Rosa Della Monica

Dr. Rosa Della Monica

1. Department of Neuroscience and Reproductive and Odontostomatological Sciences, University of Naples “Federico II”, 80131 Naples, Italy
+1

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RMRosa Della Monica
Rosa Della Monica
MCMariella Cuomo
Mariella Cuomo
MBMichela Buonaiuto
Michela Buonaiuto
DCDavide Costabile
Davide Costabile
RFRaduan Ahmed Franca
Raduan Ahmed Franca
Roberta ViscontiRoberta Visconti
Roberta Visconti
Epigenetic changes in DNA methylation contribute to the development of many diseases, including cancer. In glioblastoma multiforme, the most prevalent primary brain cancer and an incurable tumor with a median survival time of 15 months, a single epigenetic modification, the methylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene, is a valid biomarker for predicting response to therapy with alkylating agents and also, independently, prognosis. More recently, the progress from single gene to whole-genome analysis of DNA methylation has allowed a better subclassification of glioblastomas. Here, we review the clinically relevant information that can be obtained by studying MGMT gene and whole-genome DNA methylation changes in glioblastomas, also highlighting benefits, including those of liquid biopsy, and pitfalls of the different detection methods. Finally, we discuss how changes in DNA methylation, especially in glioblastomas bearing mutations in the Isocitrate Dehydrogenase (IDH) 1 and 2 genes, can be exploited as targets for tailoring therapy.

12 December 2022 in International Journal of Cancer
Verified
Journal Article
Closed access
LMLiliana Montella
Liliana Montella
MCMariella Cuomo
Mariella Cuomo
NGNunzio Del Gaudio
Nunzio Del Gaudio
MBMichela Buonaiuto
Michela Buonaiuto
DCDavide Costabile
Davide Costabile
RMRosa Della Monica
Rosa Della Monica

22 January 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
MCMariella Cuomo
Mariella Cuomo
LBLuca Borrelli
Luca Borrelli
RMRosa Della Monica
Rosa Della Monica
LCLorena Coretti
Lorena Coretti
GRGiulia De Riso
Giulia De Riso
Lorenzo ChiariottiLorenzo Chiariotti
Lorenzo Chiariotti
The bidirectional microbiota–gut–brain axis has raised increasing interest over the past years in the context of health and disease, but there is a lack of information on molecular mechanisms underlying this connection. We hypothesized that change in microbiota composition may affect brain epigenetics leading to long-lasting effects on specific brain gene regulation. To test this hypothesis, we used Zebrafish (Danio Rerio) as a model system. As previously shown, treatment with high doses of probiotics can modulate behavior in Zebrafish, causing significant changes in the expression of some brain-relevant genes, such as BDNF and Tph1A. Using an ultra-deep targeted analysis, we investigated the methylation state of the BDNF and Tph1A promoter region in the brain and gut of probiotic-treated and untreated Zebrafishes. Thanks to the high resolution power of our analysis, we evaluated cell-to-cell methylation differences. At this resolution level, we found slight DNA methylation changes in probiotic-treated samples, likely related to a subgroup of brain and gut cells, and that specific DNA methylation signatures significantly correlated with specific behavioral scores.

25 January 2023 in Pathology - Research and Practice
Verified
Journal Article
Closed access
RFRaduan Ahmed Franca
Raduan Ahmed Franca
RMRosa Della Monica
Rosa Della Monica
SCSergio Corvino
Sergio Corvino
Lorenzo ChiariottiLorenzo Chiariotti
Lorenzo Chiariotti
Maria Laura Del Basso De CaroMaria Laura Del Basso De Caro
Maria Laura Del Basso De Caro

4 June 2020 in Genes
Verified
Journal Article
Open access
PDF file
GRGiulia De Riso
Giulia De Riso
MCMariella Cuomo
Mariella Cuomo
TRTeodolinda Di Risi
Teodolinda Di Risi
RMRosa Della Monica
Rosa Della Monica
MBMichela Buonaiuto
Michela Buonaiuto
Lorenzo ChiariottiLorenzo Chiariotti
Lorenzo Chiariotti
Recessive X-linked disorders may occasionally evolve in clinical manifestations of variable severity also in female carriers. For some of such diseases, the frequency of the symptoms’ appearance during women’s life may be particularly relevant. This phenomenon has been largely attributed to the potential skewness of the X-inactivation process leading to variable phenotypes. Nonetheless, in many cases, no correlation with X-inactivation unbalance was demonstrated. However, methods for analyzing skewness have been mainly limited to Human Androgen Receptor methylation analysis (HUMARA). Recently, the X-inactivation process has been largely revisited, highlighting the heterogeneity existing among loci in the epigenetic state within inactive and, possibly, active X-chromosomes. We reasoned that gene-specific and ultra-deep DNA methylation analyses could greatly help to unravel details of the X-inactivation process and the roles of specific X genes inactivation in disease manifestations. We recently provided evidence that studying DNA methylation at specific autosomic loci at a single-molecule resolution (epiallele distribution analysis) allows one to analyze cell-to-cell methylation differences in a given cell population. We here apply the epiallele analysis at two X-linked loci to investigate whether females show allele-specific epiallelic patterns. Due to the high potential of this approach, the method allows us to obtain clearly distinct allele-specific epiallele profiles.

27 September 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
RMRosa Della Monica
Rosa Della Monica
MBMichela Buonaiuto
Michela Buonaiuto
MCMariella Cuomo
Mariella Cuomo
CPCristina Pagano
Cristina Pagano
FTFederica Trio
Federica Trio
Roberta ViscontiRoberta Visconti
Roberta Visconti
Despite intense research efforts, glioblastoma remains an incurable brain tumor with a dismal median survival time of 15 months. Thus, identifying new therapeutic targets is an urgent need. Here, we show that the lysine methyltransferase SETD8 is overexpressed in 50% of high-grade gliomas. The small molecule SETD8 inhibitor UNC0379, as well as siRNA-mediated inhibition of SETD8, blocked glioblastoma cell proliferation, by inducing DNA damage and activating cell cycle checkpoints. Specifically, in p53-proficient glioblastoma cells, SETD8 inhibition and DNA damage induced p21 accumulation and G1/S arrest whereas, in p53-deficient glioblastoma cells, DNA damage induced by SETD8 inhibition resulted in G2/M arrest mediated by Chk1 activation. Checkpoint abrogation, by the Wee1 kinase inhibitor adavosertib, induced glioblastoma cell lines and primary cells, DNA-damaged by UNC0379, to progress to mitosis where they died by mitotic catastrophe. Finally, UNC0379 and adavosertib synergized in restraining glioblastoma growth in a murine xenograft model, providing a strong rationale to further explore this novel pharmacological approach for adjuvant glioblastoma treatment.